While these molecular targeted therapies against the VEGF or mTOR signaling pathway have revolutionized the treatment of advanced RCC, no curative therapy has yet been established because RCC cells acquire resistance to these targeted treatments over a few years [14,15]. The gene discussed is VEGFA; the disease is renal cell carcinoma.